Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 9/2014

01.09.2014 | Colorectal Cancer

Insight into Mucinous Colorectal Carcinoma: Clues from Etiology

verfasst von: Niek Hugen, MD, Jasper J. P. van Beek, BSc, Johannes H. W. de Wilt, MD, Iris D. Nagtegaal, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

The prognostic impact of mucinous carcinoma (MC) in colorectal cancer (CRC) has been subject to debate ever since the introduction of the classification of tumors according to their histological differentiation. MC is a distinct clinical and pathological entity within the spectrum of CRC and accounts for approximately 10–15 % of cases. Factors involved in MC development have not been completely understood, but clinical observations may lead to a better insight into the etiology of MC. In this article, we provide an in-depth review of the literature regarding etiological aspects of MC. We show that there are worldwide differences in the prevalence of MC, with low rates in Asian countries and higher rates in the western world. Moreover, MC is more commonly diagnosed in patients suffering from inflammatory bowel diseases or Lynch syndrome and an increased rate of MC is observed in patients with radiotherapy-induced CRCs. These findings are suggestive of a different oncogenic development. Identification of conditions that are associated with MC generates insight into the etiological pathways leading to the development of this special subtype.
Literatur
1.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19(9):2814–21.PubMedCentralPubMedCrossRef
3.
Hugen N, Verhoeven RH, Radema SA, et al. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann Oncol. 2013;24(11):2819–24.PubMedCrossRef
4.
Hugen N, van de Velde CJ, de Wilt JH, et al. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651–7.PubMedCrossRef
5.
Mekenkamp LJ, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48(4):501–9.PubMedCrossRef
6.
Negri FV, Wotherspoon A, Cunningham D, et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005;16(8):1305–10.PubMedCrossRef
7.
Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer. 2009;100(6):881–7.PubMedCentralPubMedCrossRef
8.
Bosman FT. World Health Organization. International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th edn. Lyon: International Agency for Research on Cancer, 2010.
9.
Song GA, Deng G, Bell I, et al. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005;26(3):745–50.PubMed
10.
11.
Du W, Mah JT, Lee J, et al. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum. 2004;47(1):78–85.PubMedCrossRef
12.
Sasaki S, Masaki T, Umetani N, et al. Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observations. Jpn J Clin Oncol. 1998;28(3):202–6.PubMedCrossRef
13.
Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum. 2003;46(2):160–7.PubMedCrossRef
14.
Yamaguchi T, Taniguchi H, Fujita S, et al. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. Histopathology. 2012;61(2):162–9.PubMedCrossRef
15.
Numata M, Shiozawa M, Watanabe T, et al. The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease. World J Surg Oncol. 2012;10:109.PubMedCentralPubMedCrossRef
16.
Lee WS, Chun HK, Lee WY, et al. Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. Am J Surg. 2007;194(3):294–8.PubMedCrossRef
17.
You JF, Hsieh LL, Changchien CR, et al. Inverse effects of mucin on survival of matched hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer patients. Clin Cancer Res. 2006;12(14 Pt 1):4244–50.PubMedCrossRef
18.
Song W, Wu SJ, He YL, et al. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chin Med J (Engl). 2009;122(13):1486–91.PubMed
19.
Gao P, Song YX, Xu YY, et al. Does the prognosis of colorectal mucinous carcinoma depend upon the primary tumour site? Results from two independent databases. Histopathology. 2013;63(5):603–15.PubMed
20.
Kaw LL Jr, Punzalan CK, Crisostomo AC, et al. Surgical pathology of colorectal cancer in Filipinos: implications for clinical practice. J Am Coll Surg. 2002;195(2):188–95.PubMedCrossRef
21.
22.
Kang H, O’Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48(6):1161–8.PubMedCrossRef
23.
Xie L, Villeneuve PJ, Shaw A. Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. Int J Oncol. 2009;34(4):1109–15.PubMedCrossRef
24.
Morikawa T, Kuchiba A, Qian ZR, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol. 2012;19(6):1944–53.PubMedCentralPubMedCrossRef
25.
Engeland A, Tretli S, Austad G, et al. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control. 2005;16(8):987–96.PubMedCrossRef
26.
Erichsen R, Baron JA, Stoffel EM, et al. Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study. Am J Gastroenterol. 2013;108(8):1332–40.PubMedCrossRef
27.
Nitsche U, Zimmermann A, Spath C, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258(5):775–83.PubMedCentralPubMedCrossRef
28.
Papadopoulos VN, Michalopoulos A, Netta S, et al. Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol. 2004;8(Suppl 1):s123–5.PubMedCrossRef
29.
Benatti P, Gafa R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11(23):8332–40.PubMedCrossRef
30.
Safaee A, Moghimi-Dehkordi B, Fatemi SR, et al. Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev. 2010;11(5):1373–5.PubMed
31.
Veruttipong D, Soliman AS, Gilbert SF, et al. Age distribution, polyps and rectal cancer in the Egyptian population-based cancer registry. World J Gastroenterol. 2012;18(30):3997–4003.PubMedCentralPubMedCrossRef
32.
Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res. 2013;19(12):3285–96.PubMedCrossRef
33.
Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.PubMedCrossRef
34.
35.
Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789–99.PubMedCrossRef
36.
37.
Savoca PE, Ballantyne GH, Cahow CE. Gastrointestinal malignancies in Crohn’s disease. A 20-year experience. Dis Colon Rectum. 1990;33(1):7–11.PubMedCrossRef
38.
Sugita A, Greenstein AJ, Ribeiro MB, et al. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg. 1993;218(2):189–95.PubMedCentralPubMedCrossRef
39.
Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35(7):950–4.PubMedCentralPubMedCrossRef
40.
Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994;35(10):1419–23.PubMedCentralPubMedCrossRef
41.
Rubio CA, Befrits R. Colorectal adenocarcinoma in Crohn’s disease: a retrospective histologic study. Dis Colon Rectum. 1997;40(9):1072–8.PubMedCrossRef
42.
Mayer R, Wong WD, Rothenberger DA, et al. Colorectal cancer in inflammatory bowel disease: a continuing problem. Dis Colon Rectum. 1999;42(3):343–7.PubMedCrossRef
43.
Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn’s colitis: a retrospective comparative study with ulcerative colitis. Histopathology. 2007;50(5):574–83.PubMedCrossRef
44.
Brackmann S, Andersen SN, Aamodt G, et al. Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(1):9–16.PubMedCrossRef
45.
Higashi D, Futami K, Ishibashi Y, et al. Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res. 2011;31(7):2499–504.PubMed
46.
Watanabe T, Konishi T, Kishimoto J, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17(3):802–8.PubMedCrossRef
47.
Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60(13):3333–7.PubMed
48.
49.
Gasche C, Chang CL, Rhees J, et al. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res. 2001;61(20):7444–8.PubMed
50.
Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer. 2002;94(5):1421–7.PubMedCrossRef
51.
Sanchez JA, Dejulius KL, Bronner M, et al. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Inflamm Bowel Dis. 2011;17(9):1966–70.PubMedCrossRef
52.
Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369–78.PubMed
53.
Zhang H, Evertsson S, Sun X. Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol. 1999;14(6):1057–61.PubMed
54.
King-Yin Lam A, Ong K, Ho YH. Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression. Dis Colon Rectum. 2006;49(9):1275–83.PubMedCrossRef
55.
Hanski C, Bornhoeft G, Shimoda T, et al. Expression of p53 protein in invasive colorectal carcinomas of different histologic types. Cancer. 1992;70(12):2772–7.PubMedCrossRef
56.
Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 1996;56(6):1237–40.PubMed
57.
Edwards RA, Witherspoon M, Wang K, et al. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res. 2009;69(16):6423–9.PubMedCentralPubMedCrossRef
58.
Chang CL, Marra G, Chauhan DP, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol. 2002;283(1):C148–54.PubMedCrossRef
59.
Iwashita J, Sato Y, Sugaya H, et al. mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol. 2003;81(4):275–82.PubMedCrossRef
60.
Okudaira K, Kakar S, Cun L, et al. MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol. 2010;36(4):765–75.PubMed
61.
Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62(4):630–49.PubMedCrossRef
62.
63.
Slaughter DP, Southwick HW. Mucosal carcinomas as a result of irradiation. AMA Arch Surg. 1957;74(3):420–9.PubMedCrossRef
64.
Smith J. Carcinoma of the rectum following irradiation of carcinoma of the cervix. Proc R Soc Med. 1962;55:701–2.PubMedCentralPubMed
65.
Black WC 3rd, Ackerman LV. Carcinoma of the large intestine as a late complication of pelvic radiotherapy. Clin Radiol. 1965;16:278–81.PubMedCrossRef
66.
Pemberton M, Lendrum J. Squamous-cell carcinoma of the caecum following ovarian adenocarcinoma. Br J Surg. 1968;55(4):273–6.PubMedCrossRef
67.
DeCosse JJ, Rhodes RS, Wentz WB, et al. The natural history and management of radiation induced injury of the gastrointestinal tract. Ann Surg. 1969;170(3):369–84.PubMedCentralPubMedCrossRef
68.
Localio SA, Stone A, Friedman M. Surgical aspects of radiation enteritis. Surg Gynecol Obstet. 1969;129(6):1163–72.PubMed
69.
MacMahon CE, Rowe JW. Rectal reaction following radiation therapy of cervical carcinoma: particular reference to subsequent occurrence of rectal carcinoma. Ann Surg. 1971;173(2):264–9.PubMedCentralPubMedCrossRef
70.
Castro EB, Rosen PP, Quan SH. Carcinoma of large intestine in patients irradiated for carcinoma of cervix and uterus. Cancer. 1973;31(1):45–52.PubMedCrossRef
71.
Cunningham MP, Wilhoite R. Radiation-induced carcinoma of the transverse colon: report of a case. Dis Colon Rectum. 1973;16(2):145–8.PubMedCrossRef
72.
Qizilbash AH. Radiation-induced carcinoma of the rectum. A late complication of pelvic irradiation. Arch Pathol. 1974;98(2):118–21.PubMed
73.
Burri B, Mosimann R. A propos de quatre tumeurs malignes colo-rectales et du péritoine apparues après irradiation pelvienne. Helv Chir Acta. 1978;45:101–4.PubMed
74.
Greenwald R, Barkin JS, Hensley GT, et al. Cancer of the colon as a late sequel of pelvic irradiation. Am J Gastroenterol. 1978;69(2):196–8.PubMed
75.
O’Connor TW, Rombeau JL, Levine HS, et al. Late development of colorectal cancer subsequent to pelvic irradiation. Dis Colon Rectum. 1979;22(2):123–8.PubMedCrossRef
76.
Sabio H, Teja K, Elkon D, et al. Adenocarcinoma of the colon following the treatment of Wilms tumor. J Pediatr. 1979;95(3):424–6.PubMedCrossRef
77.
Martins A, Sternberg SS, Attiyeh FF. Radiation-induced carcinoma of the rectum. Dis Colon Rectum. 1980;23(8):572–5.PubMedCrossRef
78.
Tan BC, Chia KB. Radiation induced cancer: a report of ten cases. Ann Acad Med Singapore. 1981;10(3):267–76.PubMed
79.
Jao SW, Beart RW Jr, Reiman HM, et al. Colon and anorectal cancer after pelvic irradiation. Dis Colon Rectum. 1987;30(12):953–8.PubMedCrossRef
80.
Hareyama M, Okubo O, Oouchi A, et al. A case of carcinoma of the rectum after radiotherapy for carcinoma of the cervix. Radiat Med. 1989;7(4):197–200.PubMed
81.
82.
Shirouzu K, Isomoto H, Morodomi T, et al. Clinicopathologic characteristics of large bowel cancer developing after radiotherapy for uterine cervical cancer. Dis Colon Rectum. 1994;37(12):1245–9.PubMedCrossRef
83.
Kimura T, Iwagaki H, Hizuta A, et al. Colorectal cancer after irradiation for cervical cancer–case reports. Anticancer Res. 1995;15(2):557–8.PubMed
84.
Morita H, Koyama N, Tamura Y. Development of flat adenoma and superficial rectal cancer after pelvic radiation. J Clin Gastroenterol. 1998;26(3):171–4.PubMedCrossRef
85.
Minami K, Matsuzaki S, Hayashi N, et al. Immunohistochemical study of p53 overexpression in radiation-induced colon cancers. J Radiat Res. 1998;39(1):1–10.PubMedCrossRef
86.
Tamai O, Nozato E, Miyazato H, et al. Radiation-associated rectal cancer: report of four cases. Dig Surg. 1999;16(3):238–43.PubMedCrossRef
87.
Nakao A, Iwagaki H, Yoshino T, et al. Immunohistochemical studies of colorectal cancers that developed following pelvic irradiation. Surg Today. 2000;30(2):117–21.PubMedCrossRef
88.
Yokoyama S, Takifuji K, Arii K, et al. Radiation-induced rectal cancer originating from a rectocutaneous fistula: report of a case. Surg Today. 2004;34(8):706–9.PubMedCrossRef
89.
Denman DL, Kirchner FR, Osborne JW. Induction of colonic adenocarcinoma in the rat by X-irradiation. Cancer Res. 1978;38(7):1899–905.PubMed
90.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
91.
Shamsuddin AK, Elias EG. Rectal mucosa. Malignant and premalignant changes after radiation therapy. Arch Pathol Lab Med. 1981;105(3):150–1.PubMed
92.
Asayama N, Ikehara H, Yano H, et al. Endoscopic submucosal dissection of multiple flat adenomas in the radiated rectum. World J Gastrointest Endosc. 2013;5(3):128–31.PubMedCentralPubMedCrossRef
93.
Bourguignon MH, Gisone PA, Perez MR, et al. Genetic and epigenetic features in radiation sensitivity Part I: cell signalling in radiation response. Eur J Nucl Med Mol Imaging. 2005;32(2):229–46.PubMedCrossRef
94.
Sharp C, Cox R. Genetic susceptibility to radiation effects: possible implication for medical ionising radiation exposures. Eur J Nucl Med. 1999;26(4):425–8.PubMedCrossRef
95.
Nakatsuka H, Shimizu Y, Yamamoto T, et al. Colorectal cancer incidence among atomic bomb survivors, 1950–80. J Radiat Res. 1992;33(4):342–61.PubMedCrossRef
96.
Babior BM. Oxygen-dependent microbial killing by phagocytes (second of two parts). N Engl J Med. 1978;298(13):721–5.PubMedCrossRef
97.
Valko M, Rhodes CJ, Moncol J, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40.PubMedCrossRef
98.
Troll W, Wiesner R. The role of oxygen radicals as a possible mechanism of tumor promotion. Annu Rev Pharmacol Toxicol. 1985;25:509–28.PubMedCrossRef
99.
Feinendegen LE. Evidence for beneficial low level radiation effects and radiation hormesis. Br J Radiol. 2005;78(925):3–7.PubMedCrossRef
100.
Haton C, Francois A, Vandamme M, et al. Imbalance of the antioxidant network of mouse small intestinal mucosa after radiation exposure. Radiat Res. 2007;167(4):445–53.PubMedCrossRef
101.
Morgan WF. Non-targeted and delayed effects of exposure to ionizing radiation: I. Radiation-induced genomic instability and bystander effects in vitro. Radiat Res. 2003;159(5):567–80.PubMedCrossRef
102.
103.
Lyng FM, Seymour CB, Mothersill C. Production of a signal by irradiated cells which leads to a response in unirradiated cells characteristic of initiation of apoptosis. Br J Cancer. 2000;83(9):1223–30.PubMedCentralPubMedCrossRef
104.
Morgan WF, Hartmann A, Limoli CL, et al. Bystander effects in radiation-induced genomic instability. Mutat Res. 2002;504(1–2):91–100.PubMedCrossRef
105.
Lewis DA, Mayhugh BM, Qin Y, et al. Production of delayed death and neoplastic transformation in CGL1 cells by radiation-induced bystander effects. Radiat Res. 2001;156(3):251–8.PubMedCrossRef
106.
Kruidenier L, Kuiper I, Van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003;201(1):17–27.PubMedCrossRef
107.
Indaram AV, Visvalingam V, Locke M, et al. Mucosal cytokine production in radiation-induced proctosigmoiditis compared with inflammatory bowel disease. Am J Gastroenterol. 2000;95(5):1221–5.PubMedCrossRef
108.
Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137(5):1621–7.PubMedCentralPubMedCrossRef
109.
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–87 e3.
110.
Jass JR, Cottier DS, Jeevaratnam P, et al. Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer. Lancet. 1995;346(8984):1200–1.PubMedCrossRef
111.
Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001;159(6):2107–16.PubMedCentralPubMedCrossRef
112.
Shia J, Ellis NA, Paty PB, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003;27(11):1407–17.PubMedCrossRef
113.
Valle L, Perea J, Carbonell P, et al. Clinicopathologic and pedigree differences in Amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J Clin Oncol. 2007;25(7):781–6.PubMedCrossRef
114.
Jin HY, Liu X, Li VK, et al. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer. BMC Cancer. 2008;8:44.PubMedCentralPubMedCrossRef
115.
Chiang JM, Yeh CY, Changchien CR, et al. Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups. Int J Colorectal Dis. 2010;25(8):941–7.PubMedCrossRef
116.
Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology. 1996;111(2):307–17.PubMedCrossRef
117.
Leopoldo S, Lorena B, Cinzia A, et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol. 2008;15(5):1429–39.PubMedCrossRef
Metadaten
Titel
Insight into Mucinous Colorectal Carcinoma: Clues from Etiology
verfasst von
Niek Hugen, MD
Jasper J. P. van Beek, BSc
Johannes H. W. de Wilt, MD
Iris D. Nagtegaal, MD
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3706-6

Weitere Artikel der Ausgabe 9/2014

Annals of Surgical Oncology 9/2014 Zur Ausgabe

Thoracic Oncology

Three Angels are Dancing on the Head of the Esophageal Cancer Pin, but Shouldn’t We Not Topple One or Two?

Thoracic Oncology

18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer

Urologic Oncology

Prognostic Value of Diametrically Polarized Tumor-Associated Macrophages in Renal Cell Carcinoma

Urologic Oncology

External Validation of Online Predictive Models for Prediction of Cancer-specific Mortality and All-cause Mortality in Patients with Urothelial Carcinoma of the Urinary Bladder

Hepatobiliary Tumors

Effect of Body Composition on Outcomes after Hepatic Resection for Hepatocellular Carcinoma

Colorectal Cancer

Prognostic Impact of Primary Tumor Resection and Lymph Node Dissection in Stage IV Colorectal Cancer with Unresectable Metastasis: A Propensity Score Analysis in a Multicenter Retrospective Study

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.